Skip to main content
. 2013 Feb 28;8(2):e57182. doi: 10.1371/journal.pone.0057182

Table 1. Primers used in this study.

Primer Directiona Sequenceb Target gene product Product size (bp)
ldh-p01 Fw(ApaI) 5′-agggggccctctcgaacagcagtgatacc-3′ ldh promoter 1,110
ldh-p02 Rev(XhoI) 5′-cgcctcgagacagcaccatcaccaacaag-3′
phluorin-01 Fw(XhoI) 5′-cgcctcgagagtaaaggagaagaacttttca-3′ Ecliptic pHluorin gene 723
phluorin-02 Rev(SmaI-SphI) 5′-tcccccgggggacatgcatgctttgtatagttcatccatgcc-3′
ovpcr-a Fw(XhoI) 5′-cgcctcgagatgaaagtcaaaaaaacttacgg-3′ Signal peptide and first two amino acids coding gene of spaP 120
ovpcr-b Rev 5′- gaaaagttcttctcctttactttcatcggcaaaaaccttttg-3′
ovpcr-c Fw 5′-caaaaggtttttgccgatgaaagtaaaggagaagaacttttc-3′ Ecliptic pHluorin gene and linker 747
ovpcr-d Rev 5′-tcactagtagtggtcgtaccggtcccgccgcttccgccgctggacatgcatgctttgta-3′
ovpcr-e Fw 5′-tacaaagcatgcatgtccagcggcggaagcggcgggaccggtacgaccactactagtga-3′ spaP gene absence of signal peptide and first two amino acids coding sequence 4569
ovpcr-f Rev(NotI-SphI) 5′-ataagaatgcggccgctaaactatacatgcatgctcaatctttcttagcctttaagc-3′
a

Fw, forward; Rev, reverse.

b

Restriction site sequences are underlined.

HHS Vulnerability Disclosure